Health Condition 1: J151- Pneumonia due to Pseudomonas
Conditions
Interventions
Intervention1: Atorvastatin: Atorvastatin will be given at a dose of 20 mg once daily at night to all recruited patients in ICU 1 for 4 months.
Then after cross over the study drug will be given at
Sponsors
BHU TRAUMA CENRE
Eligibility
Inclusion criteria
Inclusion criteria: All critically ill adult trauma patients aged 18-60 years,admitted to ICU within 2 days of hospital admission.
Exclusion criteria
Exclusion criteria: Refusal by patients or patients relative to give consent. Patients having contraindications to statins. Crush injury. Diabetes mellitus patients. Stroke patients. LFT derranged or liver failure patients. Patients admitted only for observation of post operative elective general,orthopaedics or neuro surgery cases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Incidence of VAP 2) 14 days and 30 days mortality.Timepoint: Endotracheal culture and sensisitivity to be sent on 3rd day of ICU stay and each time fever is there, till 30 days or till the death or discharge of the patient from ICU, whichever is earlier. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) synergysm of study drugs with carbapenem, 2) escalation/de-escalation of dose of carbapenemTimepoint: On the day of first fever onset or any signs of VAP, then everyday for escalation or de-escalation of carbapenem. | — |
Countries
India
Contacts
Public ContactDr Badri Prasad Das
Department of Anaesthesiology,Institute of medical sciences,Banaras Hindu University
Outcome results
None listed